Literature DB >> 2187012

The effect of obstruction on the biliary excretion of cefoperazone and ceftazidime.

J W Leung1, R C Chan, S W Cheung, J Y Sung, S C Chung, G L French.   

Abstract

The biliary excretion of cefoperazone and ceftazidime was studied by endoscopic cannulation of the common bile duct, in patients with complete biliary obstruction and in an unobstructed control group. Patients were given each drug prophylactically for 24 h before endoscopy and as a single dose at the time of cannulation. In unobstructed patients biliary excretion of ceftazidime was passive. At the time of cannulation bile contained 10% of the peak serum concentration, rising to 20% 90 min later. Cefoperazone excretion was active. At cannulation biliary concentrations were 200% of the serum peak, 900% at 60 min and 700% at 90 min. In obstructed patients, bile sampled immediately at decompression contained neither antibiotic. Passive excretion of both drugs occurred rapidly after relief of obstruction and biliary concentrations were 20% of maximum serum levels at 60 min. Twenty-four hours later passive excretion had further improved, but the active excretion mechanism of cefoperazone had still not recovered. We conclude that obstruction impairs active as well as passive biliary excretion of antibiotics, that drainage is essential for the control of sepsis in obstructed cholangitis, and that both cefoperazone and ceftazidime achieve similar and therapeutic concentrations in bile during the 24 h after decompression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2187012     DOI: 10.1093/jac/25.3.399

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Effect of biliary obstruction on the hepatic excretion of imipenem-cilastatin.

Authors:  J W Leung; C Y Chan; C W Lai; T C Ko; A F Cheng; G L French
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Towards safer endoscopic retrograde cholangiopancreatography.

Authors:  J Thornton; A Axon
Journal:  Gut       Date:  1993-06       Impact factor: 23.059

3.  Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract.

Authors:  S J van den Hazel; X H de Vries; P Speelman; J Dankert; G N Tytgat; K Huibregtse; D J van Leeuwen
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

4.  Antimicrobial therapy for acute cholangitis: Tokyo Guidelines.

Authors:  Atsushi Tanaka; Tadahiro Takada; Yoshifumi Kawarada; Yuji Nimura; Masahiro Yoshida; Fumihiko Miura; Masahiko Hirota; Keita Wada; Toshihiko Mayumi; Harumi Gomi; Joseph S Solomkin; Steven M Strasberg; Henry A Pitt; Jacques Belghiti; Eduardo de Santibanes; Robert Padbury; Miin-Fu Chen; Giulio Belli; Chen-Guo Ker; Serafin C Hilvano; Sheung-Tat Fan; Kui-Hin Liau
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-01-30

Review 5.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

Review 6.  Biliary tract infections: a guide to drug treatment.

Authors:  J F Westphal; J M Brogard
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

Review 7.  Diagnosis and management of acute cholangitis.

Authors:  John G Lee
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-08-04       Impact factor: 46.802

8.  In vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis.

Authors:  Andreas Weber; Wolfgang Huber; Klaus Kamereck; Philipp Winkle; Petra Voland; Hans Weidenbach; Roland M Schmid; Christian Prinz
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

9.  Preoperative antimicrobial administration for prevention of postoperative infection in patients with laparoscopic cholecystectomy.

Authors:  Kazuhisa Uchiyama; Manabu Kawai; Hironobu Onishi; Masaji Tani; Hiroyuki Kinoshita; Masaki Ueno; Hiroki Yamaue
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

Review 10.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.